Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.

ABSTRACT: The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-based treatment intensification over continued standard therapy with CHOP (plus rituximab (R) in CD20-positive lymphomas). We hypothesized that PET analysis of all lymphoma manifestations may identify patients who benefitted from treatment intensification. A previously developed neural network was employed for iPET analysis to identify the highest pathological FDG uptake (max-SUV_AI) and the mean FDG uptake of all lymphoma manifestations (mean-SUV_AI). High mean-SUV_AI uptake was determined separately for iPET-positive and iPET-negative patients. The endpoint was time-to-progression (TTP). There was a significant interaction of additional rituximab and mean-SUV_AI in

SUBMITTER: Seifert R 

PROVIDER: S-EPMC9712103 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature